Osborne A, Zhang H, Yang W M, Seto E, Blanck G
Department of Biochemistry and Molecular Biology, College of Medicine, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida 33612, USA.
Mol Cell Biol. 2001 Oct;21(19):6495-506. doi: 10.1128/MCB.21.19.6495-6506.2001.
Expression of the retinoblastoma tumor suppressor protein (Rb) is required for gamma interferon (IFN-gamma)-inducible major histocompatibility complex class II gene expression and transcriptionally productive HLA-DRA promoter occupancy in several human tumor cell lines. Treatment of these Rb-defective tumor cell lines with histone deacetylase (HDAC) inhibitors rescued IFN-gamma-inducible HLA-DRA and -DRB mRNA and cell surface protein expression, demonstrating repression of these genes by endogenous cellular HDAC activity. Additionally, Rb-defective, transcriptionally incompetent tumor cells retained the HLA-DRA promoter DNase I-hypersensitive site. Thus, HDAC-mediated repression of the HLA-DRA promoter occurs following the establishment of an apparent nucleosome-free promoter region and before transcriptionally productive occupancy of the promoter by the required transactivators. Repression of HLA-DRA promoter activation by HDAC activity likely involves a YY1 binding element located in the first exon of the HLA-DRA gene. Chromatin immunoprecipitation experiments localized YY1 to the HLA-DRA gene in Rb-defective tumor cells. Additionally, mutation of the YY1 binding site prevented repression of the promoter by HDAC1 and partially prevented activation of the promoter by trichostatin A. Mutation of the octamer element also significantly reduced the ability of HDAC1 to confer repression of inducible HLA-DRA promoter activation. Treatment of Rb-defective tumor cells with HDAC inhibitors greatly reduced the DNA binding activity of Oct-1, a repressor of inducible HLA-DRA promoter activation. These findings represent the first evidence that HDAC activity can repress IFN-gamma-inducible HLA class II gene expression and also demonstrate that HDAC activity can contribute to promoter repression following the establishment of a DNase I-hypersensitive chromatin conformation.
在几种人类肿瘤细胞系中,视网膜母细胞瘤肿瘤抑制蛋白(Rb)的表达是γ干扰素(IFN-γ)诱导的主要组织相容性复合体II类基因表达以及转录活性HLA-DRA启动子占据所必需的。用组蛋白脱乙酰酶(HDAC)抑制剂处理这些Rb缺陷型肿瘤细胞系可挽救IFN-γ诱导的HLA-DRA和-DRB mRNA以及细胞表面蛋白表达,表明内源性细胞HDAC活性对这些基因具有抑制作用。此外,Rb缺陷型、转录无活性的肿瘤细胞保留了HLA-DRA启动子的DNase I超敏位点。因此,HDAC介导的HLA-DRA启动子抑制发生在明显的无核小体启动子区域形成之后,以及所需反式激活因子对启动子进行转录活性占据之前。HDAC活性对HLA-DRA启动子激活的抑制可能涉及位于HLA-DRA基因第一外显子中的YY1结合元件。染色质免疫沉淀实验将YY1定位到Rb缺陷型肿瘤细胞中的HLA-DRA基因上。此外,YY1结合位点的突变可阻止HDAC1对启动子的抑制,并部分阻止曲古抑菌素A对启动子的激活。八聚体元件的突变也显著降低了HDAC1抑制诱导型HLA-DRA启动子激活的能力。用HDAC抑制剂处理Rb缺陷型肿瘤细胞可大大降低Oct-1的DNA结合活性,Oct-1是诱导型HLA-DRA启动子激活的一种抑制因子。这些发现首次证明HDAC活性可抑制IFN-γ诱导的HLA II类基因表达,同时也表明HDAC活性可在DNase I超敏染色质构象形成后促进启动子抑制。